T-cell-induced metabolic changes can affect the fate of GBM cells via SLC7A11, and tumour metabolism also promotes immune evasion by inducing SLC7A11-mediated T-cell activation dysfunction. This evidence concerns the gene SLC7A11 and neoplasm.